In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

  • First Published: 4/7/2005
  • Last Modified: 2/11/2012

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Phase III Randomized Study of Paclitaxel Versus Polyglutamate Paclitaxel as Consolidation/Maintenance Therapy Versus No Further Anticancer Therapy Until Disease Progression in Patients With Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer or Fallopian Tube Cancer

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActiveNot specifiedNCIGOG-0212
NCT00108745

Objectives

Primary

  1. Compare overall survival of patients with stage III or IV ovarian epithelial or primary peritoneal cancer or fallopian tube cancer in clinical complete response after prior primary platinum and taxane-based chemotherapy treated with paclitaxel vs polyglutamate paclitaxel as consolidation/maintenance therapy vs no further anticancer therapy until documented disease progression.

Secondary

  1. Compare progression-free survival of patients treated with these drugs.
  2. Compare the toxicity profile of these drugs, particularly peripheral neuropathy, in these patients.
  3. Compare the quality of life of patients treated with these drugs.

Tertiary

  1. Correlate angiogenic marker expression with overall or progression-free survival of patients treated with these drugs.

Entry Criteria

Disease Characteristics:

  • Histologically confirmed stage III or IV ovarian epithelial or primary peritoneal cancer or fallopian tube cancer

  • The following histologic epithelial cell types are allowed:
    • Serous adenocarcinoma
    • Endometrioid adenocarcinoma
    • Mucinous adenocarcinoma
    • Undifferentiated carcinoma
    • Clear cell adenocarcinoma
    • Mixed epithelial carcinoma
    • Transitional cell carcinoma
    • Malignant Brenner tumor
    • Adenocarcinoma not otherwise specified

  • The following histologic cell types are not allowed:
    • Germ cell tumor
    • Sex cord-stromal tumor
    • Carcinosarcoma
    • Mixed müllerian tumor or carcinosarcoma
    • Metastatic carcinoma from other sites to the ovary
    • Low malignant potential (LMP) tumor (borderline carcinoma), including micropapillary serous carcinoma
      • Patients with a prior diagnosis of LMP tumor that was surgically resected and who subsequently developed invasive adenocarcinoma are eligible provided patient did not receive prior chemotherapy for the ovarian LMP tumor

  • Must have undergone surgery for ovarian epithelial or primary peritoneal cancer AND have tissue available for histologic evaluation
    • Optimal (≤ 1 cm) residual disease OR suboptimal residual disease after initial surgery

  • Must have completed at least 5, but no more that 8 courses of primary therapy comprising carboplatin (IV or intraperitoneal) AND paclitaxel or docetaxel-based combination chemotherapy within the past 12 weeks AND have no symptoms of persistent cancer after completion of therapy
    • CT scan of the abdomen and/or pelvis normal
    • CA 125 normal

  • Patients treated with neo-adjuvant platinum-taxane chemotherapy for a presumptive diagnosis of stage III or IV primary peritoneal carcinoma or epithelial ovarian carcinoma (by paracentesis, percutaneous biopsy or open biopsy) are eligible provided the following criteria is met:
    • Must have undergone interval abdominal surgery after at least one but no more than 6 courses of standard chemotherapy
      • Surgery must meet the same criteria as the up front surgery, including tissue diagnosis for confirmation of primary tumor site and stage III or IV disease
      • Patients must have received at least 2 courses after interval abdominal surgery

  • No synchronous primary endometrial cancer or history of primary endometrial cancer, unless all of the following criteria are met:
    • Stage ≤ IB
    • Less than 3 mm invasion without vascular or lymphatic invasion
    • No poorly differentiated subtypes, including papillary serous, clear cell, or other FIGO grade 3 lesion

Prior/Concurrent Therapy:

Biologic therapy

  • No prior biologic therapy (e.g., bevacizumab or erlotinib) for any other abdominal or pelvic tumor

Chemotherapy

  • See Disease Characteristics
  • No prior polyglutamate paclitaxel
  • No prior chemotherapy for any other abdominal or pelvic tumor
  • More than 3 years since prior adjuvant chemotherapy for localized breast cancer AND no recurrent or metastatic disease

Endocrine therapy

  • Not specified

Radiotherapy

  • No prior radiotherapy to any portion of the abdominal cavity or pelvis
  • More than 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin AND no recurrent or metastatic disease

Surgery

  • See Disease Characteristics

Other

  • No prior investigational therapy for any other abdominal or pelvic tumor
  • No prior anticancer therapy that would preclude study therapy
  • No concurrent amifostine or other protective agents

Patient Characteristics:

Age

  • Not specified

Performance status

  • GOG 0-2

Life expectancy

  • Not specified

Hematopoietic

  • Absolute neutrophil count ≥ 1,500/mm3
  • Platelet count ≥ 100,000/mm3
  • No active bleeding

Hepatic

  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • SGOT ≤ 2.5 times ULN
  • Alkaline phosphatase ≤ 2.5 times ULN
  • PT or PTT normal
  • No acute or chronic hepatitis

Renal

  • Creatinine ≤ 1.5 times ULN

Cardiovascular

  • Abnormal cardiac conduction (e.g., bundle branch block or heart block) allowed provided the disease has remained stable within the past 6 months
  • No unstable angina
  • No myocardial infarction within the past 6 months

Other

  • No neuropathy (sensory and motor) ≥ grade 2
  • No active infection requiring antibiotics
  • No ongoing gastrointestinal bleeding requiring blood product support
  • No circumstance that would preclude study participation
  • No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
  • Not pregnant or nursing
  • Fertile patients must agree to use an effective contraception method
  • Negative pregnancy test

Expected Enrollment

1100

A total of 1,110 patients (555 per treatment arm) will be accrued for this study within 8.5 years.

Outcomes

Primary Outcome(s)

Overall survival

Secondary Outcome(s)

Peripheral neuropathy by Gynecologic Oncology Group (GOG) NTX4 at 6 months after study enrollment
General quality of life by Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI) at 6 months after study enrollment
Exploratory assessment of several tissue and serum angiogenic markers for prognosis by immunohistochemistry and antibody array prior to treatment in courses 1 and 2
Exploratory time-dependent assessment of quality of life and peripheral neuropathy by FACT-O-TOI and GOG-NTX4 monthly during year 1 and then every 3 months for 2 years

Outline

This is a randomized, multicenter study. Patients are stratified according to disease stage at diagnosis (stage III vs stage IV); presence of macroscopic disease after initial debulking surgery (yes vs no); type of prior taxane-based therapy (docetaxel vs paclitaxel); and route of prior platinum therapy (intraperitoneal vs IV). Patients are randomized to 1 of 3 treatment arms.

  • Arm I: Patients receive polyglutamate paclitaxel IV over 10-20 minutes on day 1.

  • Arm II: Patients receive paclitaxel IV over 3 hours on day 1.

  • Arm III: Patients receive no further anticancer treatment until evidence of disease progression.

In arms I and II, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, before courses 3, 5, and 7 of study treatment, at completion of study treatment, and then at 1 year after completion of study treatment.

After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years.

Trial Contact Information

Trial Lead Organizations

Gynecologic Oncology Group

Larry Copeland, MD, Protocol chair
Ph: 614-293-8697
Email: larry.copeland@osumc.edu
Robert Burger, MD, Protocol co-chair
Ph: 714-456-7971
Email: raburger@uci.edu

Trial Sites

U.S.A.
Alabama
  Birmingham
 UAB Comprehensive Cancer Center
 Clinical Trials Office - UAB Comprehensive Cancer Center
Ph: 205-934-0309
Arizona
  Phoenix
 St. Joseph's Hospital and Medical Center
 Ivor Benjamin
Ph: 602-406-3000
  Scottsdale
 Mayo Clinic Scottsdale
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
Arkansas
  Little Rock
 Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
 Clinical Trial Office - Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Ph: 501-686-8274
California
  Burbank
 Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center
 Clinical Trials Office - Providence Saint Joseph Medical Center - Burbank
Ph: 818-847-3220
  La Jolla
 Rebecca and John Moores UCSD Cancer Center
 Clinical Trials Office - Rebecca and John Moores UCSD Cancer Center
Ph: 858-822-5354
  Email: cancercto@ucsd.edu
  Long Beach
 Todd Cancer Institute at Long Beach Memorial Medical Center
 Robert Bristow
Ph: 562-933-0900
  Los Angeles
 Jonsson Comprehensive Cancer Center at UCLA
 Clinical Trials Office - Jonsson Comprehensive Cancer Center at UCLA
Ph: 888-798-0719
 Kaiser Permanente Medical Center - Los Angeles
 Scott Lentz, MD
Ph: 323-783-4018
 Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
 Ilana Cass
Ph: 310-423-3277
  Mountain View
 Palo Alto Medical Foundation
 Albert Pisani
Ph: 650-934-7000
  Orange
 Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
 Clinical Trials Office - Chao Family Comprehensive Cancer Center
Ph: 877-UC-STUDY
  Email: ucstudy@uci.edu
Colorado
  Boulder
 Boulder Community Hospital
 Clinical Trials Office - Boulder Community Hospital
Ph: 303-938-5253
  Colorado Springs
 Penrose Cancer Center at Penrose Hospital
 Clinical Trials Office - Penrose Cancer Center
Ph: 719-776-5275
  Denver
 CCOP - Colorado Cancer Research Program
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
 Porter Adventist Hospital
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
 Rose Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
 St. Joseph Hospital
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Englewood
 Rocky Mountain Gynecologic Oncology
 Kevin Davis, MD
Ph: 303-781-9090
  Grand Junction
 St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Greeley
 North Colorado Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Wheat Ridge
 Exempla Lutheran Medical Center
 Clinical Trials Office - Exempla Lutheran Medical Center
Ph: 303-403-3605
Connecticut
  Farmington
 Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
 Clinical Trials Office - Carole and Ray Neag Comprehensive Cancer Center
Ph: 800-579-7822
  Hartford
 Helen and Harry Gray Cancer Center at Hartford Hospital
 Clinical Trials Office - Helen and Harry Gray Cancer Center
Ph: 860-545-5363
 Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
 Philip Stella, MD
Ph: 734-712-1000
  New Britain
 George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
 Clinical Trials Office - George Bray Cancer Center
Ph: 860-224-5660
Delaware
  Lewes
 Tunnell Cancer Center at Beebe Medical Center
 Clinical Trials Office - Tunnell Cancer Center
Ph: 302-645-3171
  Newark
 CCOP - Christiana Care Health Services
 Clinical Trial Office - CCOP - Christiana Care Health Services
Ph: 302-623-4450
Florida
  Clearwater
 Morton Plant Hospital
 Hector Arango, MD
Ph: 727-446-2111
  Fort Myers
 Florida Gynecologic Oncology - Fort Myers
 Edward Grendys, MD
Ph: 239-992-0077
  Jacksonville
 Mayo Clinic - Jacksonville
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
  Orlando
 Florida Hospital Cancer Institute at Florida Hospital Orlando
 Clinical Trials Office - Florida Hospital Cancer Institute
Ph: 407-303-5623
 M.D. Anderson Cancer Center at Orlando
 Veronica Schimp
Ph: 407-648-3800
800-648-3818
  Saint Petersburg
 Women's Cancer Associates
 James LaPolla, MD
Ph: 727-821-9688
  Sarasota
 Sarasota Memorial Hospital
 Clinical Trials Office - Sarasota Memorial Hospital
Ph: 941-917-2225
Georgia
  Columbus
 John B. Amos Cancer Center
 Clinical Trials Office - John B. Amos Cancer Center
Ph: 706-660-6404
  Gainesville
 Northeast Georgia Medical Center
 Andrew Green
Ph: 770-535-3553
  Macon
 Central Georgia Gynecologic Oncology
 Gary Eddy, MD
Ph: 476-633-6090
  Savannah
 Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
 Clinical Trials Office - Curtis and Elizabeth Anderson Cancer Institute
Ph: 912-350-8568
Illinois
  Chicago
 Robert H. Lurie Comprehensive Cancer Center at Northwestern University
 Clinical Trials Office - Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Ph: 312-695-1301
  Email: cancer@northwestern.edu
 Rush University Medical Center
 Clinical Trials Office - Rush University Medical Center
Ph: 312-942-5498
  Email: clinical_trials@rush.edu
 University of Illinois Cancer Center
 Clinical Trial Office - University of Illinois Cancer Center
Ph: 312-355-3046
  Decatur
 Decatur Memorial Hospital Cancer Care Institute
 Clinical Trials Office - Decatur Memorial Hospital Cancer Care Institute
Ph: 217-876-4750
  Hinsdale
 Gynecologic Oncology
 Sudarshan Sharma, MD
Ph: 630-856-6757
  Park Ridge
 Advocate Lutheran General Cancer Care Center
 Clinical Trials Office - Advocate Lutheran General Cancer Care Center
Ph: 847-384-3621
  Springfield
 Regional Cancer Center at Memorial Medical Center
 Clinical Trials Office - Regional Cancer Center at Memorial Medical Center
Ph: 217-788-4233
  Urbana
 CCOP - Carle Cancer Center
 Clinical Trials Office - CCOP - Carle Cancer Center
Ph: 800-446-5532
  Warrenville
 Central Dupage Cancer Center
 Laura Horvath
Ph: 630-933-1600
Indiana
  Elkhart
 Elkhart General Hospital
 Michael Method, MD, MPH
Ph: 574-237-1328
 Michiana Hematology-Oncology, PC - Elkhart
 Michael Method, MD, MPH
Ph: 574-237-1328
  Indianapolis
 Gynecologic Oncology of Indiana
 David Moore
Ph: 317-851-2555
 Indiana University Melvin and Bren Simon Cancer Center
 Clinical Trials Office - Indiana University Cancer Center
Ph: 317-274-2552
  Kokomo
 Howard Community Hospital
 Michael Method, MD, MPH
Ph: 574-237-1328
  La Porte
 Center for Cancer Therapy at LaPorte Hospital and Health Services
 Michael Method, MD, MPH
Ph: 574-237-1328
  Mishawaka
 Michiana Hematology-Oncology, PC - South Bend
 Michael Method, MD, MPH
Ph: 574-237-1328
 Saint Joseph Regional Medical Center
 Michael Method, MD, MPH
Ph: 574-237-1328
  South Bend
 CCOP - Northern Indiana CR Consortium
 Michael Method, MD, MPH
Ph: 574-237-1328
 Memorial Hospital of South Bend
 Clinical Trials Office - Memorial Hospital of South Bend
Ph: 800-284-7370
 Michiana Hematology-Oncology, PC - South Bend
 Michael Method, MD, MPH
Ph: 574-237-1328
  Westville
 Michiana Hematology Oncology PC - La Porte
 Michael Method, MD, MPH
Ph: 574-237-1328
Iowa
  Iowa City
 Holden Comprehensive Cancer Center at University of Iowa
 Cancer Information Service
Ph: 800-237-1225
Kansas
  Chanute
 Cancer Center of Kansas, PA - Chanute
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Dodge City
 Cancer Center of Kansas, PA - Dodge City
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  El Dorado
 Cancer Center of Kansas, PA - El Dorado
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Fort Scott
 Cancer Center of Kansas - Fort Scott
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Independence
 Cancer Center of Kansas-Independence
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Kansas City
 Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
 Clinical Trials Office - Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
Ph: 913-588-4709
  Kingman
 Cancer Center of Kansas, PA - Kingman
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Newton
 Cancer Center of Kansas, PA - Newton
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Parsons
 Cancer Center of Kansas, PA - Parsons
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Prairie Village
 CCOP - Kansas City
 Rakesh Gaur, MD
Ph: 913-948-5588
  Pratt
 Cancer Center of Kansas, PA - Pratt
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Wellington
 Cancer Center of Kansas, PA - Wellington
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Wichita
 Associates in Womens Health, PA - North Review
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 Cancer Center of Kansas, PA - Wichita
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 Cancer Center of Kansas, PA - Medical Arts Tower
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 CCOP - Wichita
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 Via Christi Cancer Center at Via Christi Regional Medical Center
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Winfield
 Cancer Center of Kansas, PA - Winfield
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
Kentucky
  Lexington
 Central Baptist Hospital
 Clinical Trials Office - Central Baptist Hospital
Ph: 859-260-6425
 Lucille P. Markey Cancer Center at University of Kentucky
 Clinical Trials Office - Markey Cancer Center at University of Kentucky Chandler Medical Center
Ph: 859-257-3379
  Louisville
 Louisville Oncology at Norton Cancer Institute - Louisville
 Clinical Trials Office - Louisville Oncology
Ph: 502-629-2500
Louisiana
  Alexandria
 Tulane Cancer Center Office of Clinical Research
 Clinical Trials Office - Tulane Cancer Center
Ph: 504-988-6121
  Shreveport
 Christus Schumpert Cancer Treatment Center
 Clinical Trials Office - Christus Schumpert Cancer Treatment Center
Ph: 318-681-4763
 Feist-Weiller Cancer Center at Louisiana State University Health Sciences
 Clinical Trials Office - Feist-Weiller Cancer Center at Louisiana State University Health Sciences
Ph: 318-813-1412
Maryland
  Baltimore
 Greenebaum Cancer Center at University of Maryland Medical Center
 Clinical Trials Office - Greenebaum Cancer Center at University of Maryladn Medical Center
Ph: 800-888-8823
 Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
 Clinical Trials Office - Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
Ph: 443-777-7364
  Elkton MD
 Union Hospital of Cecil County
 Mark Borowsky
Ph: 410-398-4000
Massachusetts
  Boston
 Tufts Medical Center Cancer Center
 Michael Kelly
Ph: 617-636-6100
  Springfield
 Baystate Regional Cancer Program at D'Amour Center for Cancer Care
 Tashanna Myers
Ph: 413-794-9338
  Worcester
 UMASS Memorial Cancer Center - University Campus
 Susan Zweizig, MD
Ph: 508-334-1160
Michigan
  Ann Arbor
 Saint Joseph Mercy Cancer Center
 Philip Stella, MD
Ph: 734-712-1000
 University of Michigan Comprehensive Cancer Center
 Clinical Trials Office - University of Michigan Comprehensive Cancer Center
Ph: 800-865-1125
  Battle Creek
 Battle Creek Health System Cancer Care Center
 Martin Bury
Ph: 616-966-8000
  Big Rapids
 Mecosta County Medical Center
 Martin Bury
Ph: 231-796-8691
  Detroit
 Josephine Ford Cancer Center at Henry Ford Hospital
 Thomas Buekers
Ph: 313-916-1850
888-734-5322
  Grand Rapids
 Butterworth Hospital at Spectrum Health
 Martin Bury
Ph: 616-391-2799
 CCOP - Grand Rapids
 Martin Bury
Ph: 616-391-1230
 Gynecologic Oncology of West Michigan
 Gordon Downey, MD
Ph: 616-957-3398
 Lacks Cancer Center at Saint Mary's Health Care
 Martin Bury
Ph: 616-752-5222
  Kalamazoo
 Borgess Medical Center
 Raymond Lord, MD
Ph: 269-373-7458
 Bronson Methodist Hospital
 Raymond Lord, MD
Ph: 269-373-7458
 West Michigan Cancer Center
 Clinical Trials Office - West Michigan Cancer Center
Ph: 269-373-7458
  Muskegon
 Mercy General Health Partners
 Martin Bury
Ph: 231-672-2000
  Niles
 Michiana Hematology Oncology PC - Niles
 Michael Method, MD, MPH
Ph: 574-237-1328
  Royal Oak
 William Beaumont Hospital - Royal Oak Campus
 Clinical Trials Office - William Beaumont Hospital - Royal Oak Campus
Ph: 248-551-7695
  St. Joseph
 Lakeland Regional Cancer Care Center - St. Joseph
 Michael Method, MD, MPH
Ph: 574-237-1328
  Traverse City
 Munson Medical Center
 Martin Bury
Ph: 231-935-6202
Minnesota
  Coon Rapids
 Mercy and Unity Cancer Center at Mercy Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  Duluth
 St. Luke's Hospital Cancer Care Center
 Tanya Repka, MD, FACP
Ph: 218-726-3081
  Edina
 Fairview Southdale Hospital
 Clinical Trials Office - Fairview Southdale Hospital
Ph: 612-625-3650
  Fridley
 Mercy and Unity Cancer Center at Unity Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  Maplewood
 Minnesota Oncology Hematology, PA - Maplewood
 Patrick Flynn, MD
Ph: 612-863-8585
  Minneapolis
 Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
 Clinical Trials Office - Virginia Piper Cancer Institute
Ph: 612-863-5654
  Robbinsdale
 Humphrey Cancer Center at North Memorial Outpatient Center
 Clinical Trials Office - Humphrey Cancer Center at North Memorial Outpatient Center
Ph: 763-520-1893
  Rochester
 Mayo Clinic Cancer Center
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
  Saint Louis Park
 CCOP - Metro-Minnesota
 Patrick Flynn, MD
Ph: 612-863-8585
 Park Nicollet Cancer Center
 Patrick Flynn, MD
Ph: 612-863-8585
  Saint Paul
 United Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  St. Paul
 Regions Hospital Cancer Care Center
 Clinical Trials Office - Regions Hospital Cancer Care Center
Ph: 651-254-1517
  Woodbury
 Minnesota Oncology Hematology, PA - Woodbury
 Patrick Flynn, MD
Ph: 612-863-8585
Mississippi
  Jackson
 St. Dominic Cancer Center
 Donald Seago
Ph: 601-200-3070
 University of Mississippi Cancer Clinic
 James Thigpen, MD
Ph: 601-984-5590
  Pascagoula
 Regional Cancer Center at Singing River Hospital
 James Clarkson, MD
Ph: 228-374-6296
Missouri
  Joplin
 Freeman Cancer Institute at Freeman Health System
 David Ross
Ph: 417-347-3066
  Kansas City
 Research Medical Center
 Rakesh Gaur, MD
Ph: 913-948-5588
  Saint Louis
 David C. Pratt Cancer Center at St. John's Mercy
 Clinical Trials Office - David C. Pratt Cancer Center at St. John's Mercy
Ph: 314-251-6770
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 David Mutch, MD
Ph: 314-362-3181
  Springfield
 Hulston Cancer Center at Cox Medical Center South
 Robert Carolla
Ph: 417-269-5257
Nebraska
  Omaha
 Methodist Estabrook Cancer Center
 Peter Morris, MD
Ph: 402-354-5250
 UNMC Eppley Cancer Center at the University of Nebraska Medical Center
 Clinical Trials Office - UNMC Eppley Cancer Center at the University of Nebraska Medical Center
Ph: 800-999-5465
Nevada
  Las Vegas
 Women's Cancer Center - La Canada
 Nick Spirtos, MD
Ph: 408-866-3843
  Reno
 Renown Institute for Cancer at Renown Regional Medical Center
 Peter Lim
Ph: 775-982-5050
866-559-0558
New Hampshire
  Lebanon
 Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
 Clinical Trials Office - Norris Cotton Cancer Center
Ph: 603-650-7609
  Email: cancerhelp@dartmouth.edu
New Jersey
  Neptune
 Jersey Shore Cancer Center at Jersey Shore University Medical Center
 Henry Sprance, MD, PhD
Ph: 732-776-4128
  Voorhees
 Cancer Institute of New Jersey at Cooper - Voorhees
 Clinical Trials Office - Cancer Institute of New Jersey at Cooper University Hospital - Voorhees
Ph: 856-325-6757
New Mexico
  Albuquerque
 Southwest Gynecologic Oncology Associates, Incorporated
 Carolyn Muller, MD
Ph: 505-272-0185
 University of New Mexico Cancer Center
 Clinical Trials Office - University of New Mexico Cancer Center
Ph: 505-272-6972
New York
  Brightwaters
 Schwartz Gynecologic Oncology
 Benjamin Schwartz
Ph: 631-376-0055
  Buffalo
 Roswell Park Cancer Institute
 Clinical Trials Office - Roswell Park Cancer Institute
Ph: 877-275-7724
  Fresh Meadows
 New York Hospital Medical Center of Queens - Fresh Meadows
 Manolis Tsatsas
Ph: 718-670-1170
  Lake Success
 Monter Cancer Center of the North Shore-LIJ Health System
 Veena John
Ph: 516-734-8959
  Manhasset
 Don Monti Comprehensive Cancer Center at North Shore University Hospital
 Clinical Trials Office - Don Monti Comprehensive Cancer Center at North Shore University Hospital
Ph: 516-734-8900
  Mineola
 Winthrop University Hospital
 Jeannine Villella
Ph: 516-663-9500
  New Hyde Park
 Long Island Jewish Medical Center
 Veena John
Ph: 718-470-7000
800-371-7111
  New York
 Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
 Clinical Trials Office - Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
Ph: 212-305-8615
 Mount Sinai Medical Center
 Monica Hayes
Ph: 212-241-6500
  Stony Brook
 Stony Brook University Cancer Center
 Clinical Trials Office - Stony Brook University Cancer Center
Ph: 800-862-2215
  Syracuse
 SUNY Upstate Medical University Hospital
 Clinical Trials Office - SUNY Upstate Medical University Hospital
Ph: 315-464-5476
North Carolina
  Asheville
 Hope A Women's Cancer Center
 Timothy Vanderkwaak
Ph: 828-670-8403
  Burlington
 Alamance Cancer Center at Alamance Regional Medical Center
 Janak Choksi, MD
Ph: 336-538-7737
  Charlotte
 Presbyterian Cancer Center at Presbyterian Hospital
 Clinical Trials Office - Presbyterian Cancer Center at Presbyterian Hospital
Ph: 704-384-5369
  Durham
 Duke Cancer Institute
 Clinical Trials Office - Duke Cancer Institute
Ph: 888-275-3853
  Greensboro
 Moses Cone Regional Cancer Center at Wesley Long Community Hospital
 Clinical Trials Office - Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Ph: 336-621-8374
  Rutherfordton
 Rutherford Hospital
 David Griffin
Ph: 828-286-5000
  Wilmington
 Zimmer Cancer Center at New Hanover Regional Medical Center
 Walter Gajewski, MD
Ph: 910-342-3000
  Winston-Salem
 Wake Forest University Comprehensive Cancer Center
 Clinical Trials Office - Wake Forest University Comprehensive Cancer Center
Ph: 336-713-6771
Ohio
  Akron
 McDowell Cancer Center at Akron General Medical Center
 Eric Jenison, MD
Ph: 330-344-6041
 Summa Center for Cancer Care at Akron City Hospital
 Clinical Trials Office - Akron City Hospital
Ph: 330-375-6101
  Canton
 Aultman Cancer Center at Aultman Hospital
 Clinical Trials Office - Aultman Cancer Center at Aultman Hospital
Ph: 330-363-6891
  Cincinnati
 Charles M. Barrett Cancer Center at University Hospital
 William Richards
Ph: 806-796-1317
  Cleveland
 Case Comprehensive Cancer Center
 Clinical Trials Office - Case Comprehensive Cancer Center
Ph: 800-641-2422
 MetroHealth Cancer Care Center at MetroHealth Medical Center
 Peter Rose, MD
Ph: 216-444-1712
  Columbus
 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
 Ohio State University Cancer Clinical Trial Matching Service
Ph: 866-627-7616
  Email: osu@emergingmed.com
 Riverside Methodist Hospital Cancer Care
 Clinical Trials Office - Riverside Methodist Hospital Cancer Care
Ph: 614-566-4475
  Dayton
 David L. Rike Cancer Center at Miami Valley Hospital
 Clinical Trials Office - David L. Rike Cancer Center at Miami Valley Hospital
Ph: 937-208-2079
  Mentor
 Lake/University Ireland Cancer Center
 Steven Waggoner, MD
Ph: 216-844-5011
Oklahoma
  Oklahoma City
 Oklahoma University Cancer Institute
 Robert Mannel, MD
Ph: 405-271-8787
  Tulsa
 Cancer Care Associates - Saint Francis Campus
 Robert Mannel, MD
Ph: 405-271-8787
Oregon
  Portland
 Northwest Cancer Specialists at Rose Quarter Cancer Center
 William Winter, III
Ph: 503-228-6509
Pennsylvania
  Abington
 Rosenfeld Cancer Center at Abington Memorial Hospital
 Clinical Trials Office - Rosenfeld Cancer Center at Abington Memorial Hospital
Ph: 215-481-2402
  Danville
 Geisinger Cancer Institute at Geisinger Health
 Clinical Trials Office - Geisinger Cancer Institute
Ph: 570-271-5251
  Hazleton
 Geisinger Hazleton Cancer Center
 James Bosscher
Ph: 570-459-2901
  Hershey
 Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
 Clinical Trials Office - Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
Ph: 717-531-3779
  Email: CTO@hmc.psu.edu
  Philadelphia
 Abramson Cancer Center of the University of Pennsylvania
 Clinical Trials Office - Abramson Cancer Center of the University of Pennsylvania
Ph: 800-474-9892
  Pittsburgh
 UPMC Cancer Center at Magee-Womens Hospital
 Clinical Trials Office - UPMC Cancer Center at Magee-Womens Hospital
Ph: 412-647-2811
 Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
 Eileen Segreti, MD
Ph: 412-578-1116
  Reading
 McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
 Clinical Trials Office - McGlinn Family Regional Cancer Center
Ph: 610-988-9323
  State College
 Geisinger Medical Group - Scenery Park
 James Bosscher
Ph: 814-231-4560
  Wilkes-Barre
 Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
 Clinical Trials Office - Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
Ph: 570-271-5251
Rhode Island
  Providence
 Women and Infants Hospital of Rhode Island
 Clinical Trials Office - Women and Infants Hospital of Rhode Island
Ph: 401-274-1122
South Carolina
  Spartanburg
 CCOP - Upstate Carolina
 Clinical Trials Office - CCOP - Upstate Carolina
Ph: 800-486-5941
South Dakota
  Rapid City
 Black Hills Obstetrics & Gynecology LLP
 Helen Frederickson, MD
Ph: 605-343-9224
  Sioux Falls
 Avera Cancer Institute
 Luis Rojas-Espaillat
Ph: 605-322-3000
 Sanford Cancer Center at Sanford USD Medical Center
 Clinical Trials Office - Sanford Cancer Center
Ph: 605-328-1367
Tennessee
  Chattanooga
 Chattanooga Gyn-Oncology
 Donald Chamberlain, MD, FACS, FACOG
Ph: 423-698-2050
 Chattanooga's Program in Women's Oncology
 Stephen DePasquale
Ph: 423-266-3636
Texas
  Dallas
 Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
 Clinical Trials Office - Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Ph: 866-460-4673; 214-648-7097
  Fort Sam Houston
 Brooke Army Medical Center
 Clinical Trials Office - Brooke Army Medical Center
Ph: 210-916-4837
  Galveston
 University of Texas Medical Branch
 Clinical Trials Office - University of Texas Medical Branch
Ph: 409-772-1950
  Houston
 Lyndon B. Johnson General Hospital
 Lois Ramondetta
Ph: 713-745-0307
 M. D. Anderson Cancer Center at University of Texas
 Clinical Trials Office - M. D. Anderson Cancer Center at the University of Texas
Ph: 713-792-3245
 Methodist Hospital
 Tri Dinh
Ph: 713-441-1010
Vermont
  Burlington
 Fletcher Allen Health Care - University Health Center Campus
 Clinical Trials Office - Fletcher Allen Health Care
Ph: 802-656-8990
Virginia
  Annandale
 Northern Virginia Pelvic Surgery Associates
 John Elkas
Ph: 202-782-8513
  Charlottesville
 University of Virginia Cancer Center
 Susan Modesitt
Ph: 434-924-9333
800-223-9173
  Norfolk
 Virginia Oncology Associates - Lake Wright
 Robert Squatrito, MD
Ph: 757-466-1466
  Richmond
 Virginia Commonwealth University Massey Cancer Center
 Clinical Trials Office -Virginia Commonwealth University Massey Cancer Center
Ph: 804-628-1939
Washington
  Mount Vernon
 Skagit Valley Hospital Cancer Care Center
 Benjamin Greer, MD
Ph: 206-685-2463
  Seattle
 CCOP - Virginia Mason Research Center
 Thomas Malpass
Ph: 206-341-0446
 Fred Hutchinson Cancer Research Center
 Benjamin Greer, MD
Ph: 206-685-2463
 Northwest Hospital and Medical Center
 Benjamin Greer, MD
Ph: 206-685-2463
 Pacific Gynecology Specialists
 Benjamin Greer, MD
Ph: 206-685-2463
 Seattle Cancer Care Alliance
 Clinical Trials Office - Seattle Cancer Care Alliance
Ph: 800-804-8824
 Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
 Benjamin Greer, MD
Ph: 206-685-2463
 University Cancer Center at University of Washington Medical Center
 Benjamin Greer, MD
Ph: 206-685-2463
  Spokane
 Cancer Care Northwest - Spokane South
 Clinical Trials Office - Cancer Care Northwest - Spokane South
Ph: 509-228-1083
  Tacoma
 MultiCare Regional Cancer Center at Tacoma General Hospital
 Clinical Trials Office - MultiCare Regional Cancer Center
Ph: 253-403-3229
  Walla Walla
 St. Mary Regional Cancer Center at St. Mary Medical Center
 Benjamin Greer, MD
Ph: 206-685-2463
Wisconsin
  Green Bay
 St. Vincent Hospital Regional Cancer Center
 Clinical Trials Office - St. Vincent Hospital Regional Cancer Center
Ph: 920-433-8889
  Madison
 University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
 Clinical Trials Office - University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Ph: 608-262-5223
  Milwaukee
 Medical College of Wisconsin Cancer Center
 Clinical Trials Office - Medical College of Wisconsin Cancer Center
Ph: 414-805-4380
 Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
 Clinical Trials Office - Vince Lombardi Cancer Clinic
Ph: 414-649-5717
  Sheboygan
 Vince Lombardi Cancer Clinic - Sheboygan
 Clinical Trials Office - Vince Lombardi Cancer Clinic - Sheboygan
Ph: 414-649-7200
  Waukesha
 Waukesha Memorial Hospital Regional Cancer Center
 Clinical Trials Office - Waukesha Memorial Hospital Regional Cancer Center
Ph: 262-928-7632
  West Allis
 Aurora Women's Pavilion of West Allis Memorial Hospital
 Peter Johnson, MD (Contact information may not be current)
Ph: 262-549-6662

Registry Information
Official Title A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or XyotaxTM (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
Trial Start Date 2005-03-21
Trial Completion Date 2008-04-01 (estimated)
Registered in ClinicalTrials.gov NCT00108745
Date Submitted to PDQ 2005-02-17
Information Last Verified 2012-02-11
NCI Grant/Contract Number CA27469

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top